The Norwegian medical device company, RESPINOR, provides breakthrough technology within respiratory care.
We can all be exposed to an accident where we end up as a patient in the Intensive Care Unit (ICU) at the hospital unable to breathe and dependent on support from mechanical ventilation.
A huge medical need
Mechanical ventilation is one of the most common therapies in the ICU. It is a treatment you only receive in the most life-critical situations. A vital treatment, but also a costly one. Hence, every surplus day a patient receives mechanical ventilation, the risk of permanent damage to the breathing ability increases along with the treatment costs. This group comprises 3% of the patients at the hospital but 12% of the costs. However, today, there are no objective measurements of diaphragm function – our main breathing muscle.
RESPINOR is developing a breakthrough technology, RESPINOR DXT (Diaphragm Excursion Technology), to improve clinical decision-making in critically ill patients within the ICU. The technology covers an unmet medical need within respiratory care. RESPINOR DXT provides a non-invasive continuous monitoring of the diaphragm movement, giving healthcare professionals real-time continuous feedback.
Objective measurement of the patients’ diaphragm function can be a game-changer in this field, and that is what RESPINOR aim to provide. Market research from the US concluded that: “RESPINOR DXT has the opportunity to create a benchmark scale which could become an industry standard for assessing work of breathing.”
–Our technology has a broad range of potential benefits and represents an enabling platform for applications in critical care and other areas of respiratory medicine, says Trude Tingvoll, CEO of RESPINOR
Estimated launch 2022
RESPINOR DXT is ranked number 1 in both phase 1 & 2 in the EU commission’s Horizon 2020 program, the largest EU research and innovation program. This has secured soft funding for the ongoing clinical feasibility studies in France, Italy, and Norway for the first indication, mechanical ventilation. The estimated launch in EU is within 2022 followed by expansion into other key markets globally. The company has secured strong IP protection for their technology platform in key geographies and confirmed freedom to operate globally.
The global market within respiratory monitoring devices is expected to grow with a CAGR of 8,27% between 2017 to 2023, and the market value is estimated to USD 2.8 billion in 2023.
The total intensive care market is approximately 42 million patients annually in the EU and the US. RESPINORs initial clinical program targets mechanical ventilation with 4,5 million patients yearly, and plan to expand in due time into other areas of the patients journey during their stay at the hospital.
–Our team is looking forward to bring this break through technology to critically ill patients globally, says Tingvoll.
- RESPINOR AS is a privately-owned medical device company, founded in 2015 based on IP, prototypes and clinical development at the University of Oslo, and NeoRad AS
- RESPINOR DXT is twice ranked number 1 both in phase 1 & 2 in the EU commission’s H2020 program
- RESPINOR is developing a novel non-invasive medical technology for continuous monitoring of the diaphragm, the main breathing muscle
- Located in the Oslo Science park in Norway